Publications

Featured Publication

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

N Engl J Med 2021; 384:717-726
Brannan, S.K., Sawchak, S., et al.
View

Structural Basis of Efficacy-Driven Ligand Selectivity at GPCRs

Nature Chem Biol 2023
Powers, A. S., Pham, V., et al.
View

The Clinical Candidate Xanomeline Displays a Binate Orthosteric and Allosteric Binding and Pharmacological Profile at the M4 mACHR

American College of Psychopharmacology (ACNP) Annual Meeting; 2022 December 4-7.
Burger, W., Vuckovic, Z., et al.
Download

Safety and Tolerability of KarXT (Xanomeline-Trospium) in a Phase 2, Randomized, Double-blind, Placebo-controlled Study in Patients with Schizophrenia

Schizophr 2022; 8:109
Correll, C., Angelov, A., et al.
View

Safety and Efficacy of KarXT (Xanomeline-Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Trial (EMERGENT-2)

American College of Psychopharmacology (ACNP) Annual Meeting; 2022 December 4-7.
Paul, S., Correll, C., et al.
Download

Effectiveness of KarXT (Xanomeline-Trospium) for Cognitive Impairment in Schizophrenia: Post Hoc Analyses from a Randomised, Double-blind, Placebo-controlled Phase 2 Study

Transl Psychiatry 12, 491 (2022).
Sauder, C., Allen L. A., et al.
View

Safety and Efficacy of KarXT (Xanomeline-Trospium) in Schizophrenia in the Phase 3, Randomized, Double-blind, Placebo-controlled EMERGENT-2 Trial

Neuroscience Education Institute (NEI) Congress; 2022 November 3-6.
Correll, C., Miller, A., et al.
Download

Muscarinic Acetylcholine Receptors for Psychotic Disorders: Bench-side to Clinic

Trends Pharmacol Sci. 2022 Dec;43(12):1098-1112.
Yohn, S., Weiden, P., et al.
View